A phase III study comparing avelumab versus docetaxel as second-line therapy (JAVELIN Lung 200 trial) did not meet OS in PD-L1 positive (≥1% of tumor cells) population, the primary endpoint; PD-L1 expression and NSCLC histology were stratification criteria [54]. This evidence concerns the gene CD274 and neoplasm.